{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:47:48Z","timestamp":1781171268352,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T00:00:00Z","timestamp":1144368000000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at increased risk for invasive fungal infections (IFIs) over prolonged periods of time. Aerosolized amphotericin B lipid complex (ABLC) has shown promise in lung transplant recipients as a convenient means of delivering protective drug to the upper airways avoiding systemic toxicities. The safety and tolerability of aerosolized ABLC in 40 subjects undergoing allogeneic HSCT was prospectively investigated in an open\u2010labeled, non\u2010comparative study. Subjects received aerosolized ABLC treatment once daily for 4 days, then once weekly for 13 weeks; fluconazole was administered daily as standard of care through post\u2010transplant day 100. Pulmonary mechanics were measured before and after each dose of inhaled ABLC; adverse events (AEs) and the development of IFI were also monitored. Cough, nausea, taste disturbance, or vomiting followed 2.2% of 458 total inhaled ABLC administrations; 5.2% of inhaled ABLC administrations were associated with \u226520% decrease in pulmonary function measurements (forced expiratory volume in 1\u2003second or forced vital capacity) and none required treatment with bronchodilators or withdrawal from study. Four mild AEs were considered possibly or probably related to study treatment; no deaths or withdrawals from treatment were attributed to study drug. Of 3 proven IFIs occurring during the study period, only 1, a catheter\u2010related case of disseminated fusariosis, occurred while the subject was receiving study medication. Aerosolized ABLC was well tolerated in allogeneic HSCT recipients. With only 1 of 40 subjects developing IFI while receiving treatment, the combination of fluconazole and inhaled ABLC warrants further study as antifungal prophylaxis following allogeneic HSCT.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2006.00125.x","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T08:28:54Z","timestamp":1144398534000},"page":"13-20","source":"Crossref","is-referenced-by-count":51,"title":["Non\u2010comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"8","author":[{"given":"B.D.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Dodds Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Alspaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Perfect","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,4,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-10-199911160-00003"},{"key":"e_1_2_6_4_2","first-page":"3551","article-title":"Role of sentinel surveillance of candidemia","volume":"40","author":"Pfaller MA","year":"2002","journal-title":"trends in species distribution and antifungal susceptibility"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2644"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2512"},{"key":"e_1_2_6_7_2","first-page":"250","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo\u2010controlled, double\u2010blind, multicenter trial","volume":"28","author":"Menichetti F","year":"1999","journal-title":"GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01465.x"},{"key":"e_1_2_6_9_2","first-page":"1887","article-title":"Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia","volume":"44","author":"Harousseau JL","year":"2000","journal-title":"a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/422312"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.5.891"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90345-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702233"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.1001"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.7.1466"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.11.1676"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726364"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697981"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200108150-00036"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000101516.08327.A9"},{"key":"e_1_2_6_21_2","first-page":"7","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants","volume":"34","author":"Ascioglu S","year":"2002","journal-title":"an international consensus"},{"key":"e_1_2_6_22_2","first-page":"2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis\u2010related death in allogeneic marrow transplant recipients","volume":"96","author":"Marr KA","year":"2000","journal-title":"long-term follow-up of a randomized, placebo-controlled trial"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/516480"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/313803"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1056\/NEJM200402263500923","article-title":"Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem\u2010cell transplant","volume":"350","author":"Marty FM","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/422723"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/423274"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_2_6_29_2","first-page":"497","article-title":"Non\u2010Candida fungal infections after bone marrow transplantation","volume":"96","author":"Morrison VA","year":"1994","journal-title":"risk factors and outcome"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2006.00125.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2006.00125.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:06:22Z","timestamp":1696946782000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2006.00125.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1399-3062.2006.00125.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2006.00125.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}